FDA is using GMP Warning Letters to raise other compliance issues
Several of the past year’s GMP Warning Letters incorporated other compliance issues, including allegations of:
Unapproved new drugs
These letters suggest that the FDA is taking a more holistic
approach to enforcement when it identifies violative conduct
FDA may also start taking a closer look at pharmacovigilance
systems during future GMP inspections
© 2009 Hogan & Hartson LLP. All rights reserved.